- Home
- SIGA vs SVRA Comparison
SIGA vs SVRA Comparison
Compare SIGA & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- SVRA
- Stock Information
- Founded
- SIGA 1995
- SVRA 2007
- Country
- SIGA United States
- SVRA United States
- Employees
- SIGA N/A
- SVRA N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- SVRA Health Care
- Exchange
- SIGA Nasdaq
- SVRA Nasdaq
- Market Cap
- SIGA 515.1M
- SVRA 527.2M
- IPO Year
- SIGA 1997
- SVRA N/A
- Fundamental
- Price
- SIGA $9.13
- SVRA $3.16
- Analyst Decision
- SIGA
- SVRA Buy
- Analyst Count
- SIGA 0
- SVRA 7
- Target Price
- SIGA N/A
- SVRA $5.57
- AVG Volume (30 Days)
- SIGA 640.7K
- SVRA 1.3M
- Earning Date
- SIGA 08-05-2025
- SVRA 08-13-2025
- Dividend Yield
- SIGA 6.57%
- SVRA N/A
- EPS Growth
- SIGA N/A
- SVRA N/A
- EPS
- SIGA 1.14
- SVRA N/A
- Revenue
- SIGA $179,639,422.00
- SVRA N/A
- Revenue This Year
- SIGA N/A
- SVRA N/A
- Revenue Next Year
- SIGA $95.31
- SVRA N/A
- P/E Ratio
- SIGA $8.01
- SVRA N/A
- Revenue Growth
- SIGA 3.86
- SVRA N/A
- 52 Week Low
- SIGA $4.95
- SVRA $1.89
- 52 Week High
- SIGA $9.80
- SVRA $4.70
- Technical
- Relative Strength Index (RSI)
- SIGA 67.83
- SVRA 71.42
- Support Level
- SIGA $8.39
- SVRA $2.92
- Resistance Level
- SIGA $9.14
- SVRA $3.28
- Average True Range (ATR)
- SIGA 0.50
- SVRA 0.21
- MACD
- SIGA 0.04
- SVRA 0.04
- Stochastic Oscillator
- SIGA 84.19
- SVRA 85.88
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.